Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

CUSIP: 604749101

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 6 signals
Share change
+196,059
SEC-reported price per share
$117.07
Number of holders
70
Value change
+$25,114,759
Number of buys
40
Number of sells
26
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
60,799,281

Security key

604749101

Report period

Q2 2026

Institutions

70

Top holders

10

Ownership snapshot

Top reported holders of MIRM - Mirum Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F 13D/G Lead comparable stake: 12% 13D/G row: Janus Henderson Group Ltd. Showing 1-6 of 15 holder rows.

Quick read

Janus Henderson Group Ltd. leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership Top 5
Janus Henderson Group Ltd. 12%
Frazier Life Sciences IX, L.P. 6.8%
BlackRock, Inc. 5.7%
EVENTIDE ASSET MANAGEMENT, LLC 4.1%
BIOTECHNOLOGY VALUE FUND L P 3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Janus Henderson Group Ltd.
13F 13D/G
Company · JANUS HENDERSON GROUP PLC
12%
from 13D/G
$641,764,403
6,945,813 shares
31 Mar 2026
Frazier Life Sciences IX, L.P.
13D/G
Patrick J. Heron
6.8%
$324,522,832
4,108,404 shares
+$29,477,804 23 Jan 2026
BlackRock, Inc.
13F 13D/G
Company
5.7%
from 13D/G
$355,342,442
3,846,530 shares
31 Mar 2026
EVENTIDE ASSET MANAGEMENT, LLC
13D/G 13F
Company
4.1%
$165,372,042
2,093,582 shares
-$40,549,990 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
3%
$109,619,710
1,495,290 shares
$0 30 Sep 2025
Frazier Life Sciences Management, L.P.
13F
Company
13F
13%
$709,449,208
7,679,684 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
70
Shares
2,464,857
Rows available
70
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
308
Q2 2026 holders
70
Holder diff
-238
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .